Axsome Therapeutics Inc (AXSM)

Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie

Prediction: These 2 Growth Stocks Could Triple By 2030

The Motley Fool

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Zacks Investment Research

Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript

The Motley Fool

Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?

Zacks Investment Research

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research

TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks Investment Research

Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights

Benzinga

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Zacks Investment Research

Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?

The Motley Fool

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

GlobeNewswire Inc.

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

Zacks Investment Research

Analyst Ratings For Axsome Therapeutics

Benzinga

2 Under-the-Radar Growth Stocks to Consider

The Motley Fool

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

GlobeNewswire Inc.

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

Zacks Investment Research

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

GlobeNewswire Inc.

Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal

Zacks Investment Research

Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday

Benzinga

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

GlobeNewswire Inc.

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

GlobeNewswire Inc.

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

The Motley Fool

Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?

Zacks Investment Research

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

Zacks Investment Research

Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

Zacks Investment Research

What Analysts Are Saying About Axsome Therapeutics Stock

Benzinga

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

GlobeNewswire Inc.

What Analysts Are Saying About Axsome Therapeutics Stock

Benzinga

3 Biotech Stocks to Buy and Hold for the Next 10 Years

The Motley Fool

Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat

Zacks Investment Research

Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript

The Motley Fool

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Investment Research

Why Axsome (AXSM) Might Surprise This Earnings Season

Zacks Investment Research

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

2 Stocks That Could Double Your Money in 5 Years

The Motley Fool

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst

Benzinga

The Latest Analyst Ratings For Axsome Therapeutics

Benzinga

Cramer Praises Asset Manager's 'Amazing Quarter,' But As For SolarEdge? 'Too Hard To Own'

Benzinga

Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says

Benzinga

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks Investment Research

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

GlobeNewswire Inc.

The Analyst Landscape: 6 Takes On Axsome Therapeutics

Benzinga

Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results

Zacks Investment Research

Axsome (AXSM) Surges 7.8%: Is This an Indication of Further Gains?

Zacks Investment Research

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

GlobeNewswire Inc.

3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years

The Motley Fool

2 Biotech Stocks You Can Buy and Hold for the Next Decade

The Motley Fool

Prediction: These 3 Stocks Will Soar in 2024

The Motley Fool

Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition

Zacks Investment Research

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

GlobeNewswire Inc.